Revenue Growth Reinforces Twist Bioscience Corp.’s (TWST) Technology Leadership
Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Twist Bioscience Corp (TWST)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | NVerses Capital Jb Kim | 3,132 | $322,220 | 0.5% | |
| 2. | Bayforest Capital Theodoros Tsagaris | 320 | $32,922 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.20 | 10,000 | $132,000.00 | 29,297 | 2023-05-10 | Filing | |
| $29.25 | 8,550 | $250,096.05 | 13,939 | 2022-05-11 | Filing | |
| $14.00 | 60,000 | $840,000.00 | 954,146 | 2018-11-02 | Filing | |
| $14.00 | 15,000 | $210,000.00 | 2,407,422 | 2018-11-02 | Filing | |
| $14.00 | 60,000 | $840,000.00 | 954,146 | 2018-11-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $85.32 | 2,888 | $246,407.63 | 269,678 | 2026-08-03 | Filing | |
| $85.32 | 1,133 | $96,668.92 | 119,281 | 2026-08-03 | Filing | |
| $85.32 | 5,101 | $435,223.44 | 818,938 | 2026-08-03 | Filing | |
| $85.32 | 167 | $14,248.64 | 46,160 | 2026-08-03 | Filing | |
| $85.32 | 1,070 | $91,293.68 | 104,071 | 2026-08-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,086,779 | $111,807,823 | 0.1% | |
| 2. | 1,000,344 | $102,915,391 | 0.06% | |
| 3. | 767,364 | $78,946,408 | 0.85% | |
| 4. | 462,145 | $47,545,478 | 0.06% | |
| 5. | 453,216 | $46,626,862 | 0.03% |
News See All
Twist Bioscience (TWST) Surged on Strong Results and AI Drug Discovery Demand
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan Small Cap Fund". A copy of the letter can be downloaded here.
10 Best Performing American Stocks in June 2026
Fidelity says “Market breadth has broadly remained strong” and “unrelenting corporate earnings growth has underpinned stocks.” That suggests some recent rallies are happening in a market still...
Investor’s Favored Twist Bioscience’s (TWST) Association with Technology Companies
Osterweis Capital Management, an investment management firm, released its Q1 2026 investor update for its “Osterweis Opportunity Fund”. A copy of the letter can be downloaded here.
Is Twist Bioscience Corporation (TWST) a Strong Buy After Guggenheim Lifts Price Target?
TheFly reported on May 5 that a Guggenheim analyst increased the price target on TWST from $55 to $60 while maintaining a Buy rating on the stock.
8 Best Immunology Stocks to Buy According to Hedge Funds
Despite growing geopolitical tensions related to the Iran war, Callanish Capital CEO Haig Bathgate shared an optimistic stance on global markets during an appearance on CNCB on May 7.
10 Best ARK Stocks to Buy Right Now
On January 15, Cathie Wood, in her Outlook for 2026, said that the US economy has formed a "coiled spring," referencing ARK Investment Management analysis.
Twist Bioscience Corporation (TWST) Announces Q2 2026 Financial Results
Twist Bioscience Corporation (NASDAQ:TWST) is one of the best performing healthcare stocks so far in 2026.
10 Best Performing Healthcare Stocks So Far in 2026
She was of the view that the backdrop at present is featuring geopolitical tensions, Fed policy uncertainty, inflation concerns, and still, it is incredible that the stock market is at record highs.
Twist Bioscience Corp (TWST) Climbed on Earnings Beat
Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here.
Hedge Fund Resource Center